SenesTech 2025 Q3 Earnings Record Revenue Growth of 43% Drives Improved EBITDA

SenesTech (SNES) reported fiscal 2025 Q3 earnings on Nov 11, 2025, with revenue surging 43.2% year-over-year to $690,000. The company improved its adjusted EBITDA loss to $1.2 million, a record for SenesTech, while narrowing net losses. Despite the progress, the stock remains unprofitable, with a 16.8% month-to-date decline, underscoring mixed investor sentiment.

Revenue

Total revenue for the quarter reached $690,000, with Revenues, net also reported at $690,000, indicating no discrepancies between the two figures. The growth was driven by the Evolve® Rodent Birth Control product line, which now accounts for 85% of total revenue, up from 69% in the prior-year period. E-commerce sales, now representing over 50% of revenue, surged 55% year-over-year, while municipal deployments and retail partnerships also contributed to the top-line expansion.

Earnings/Net Income

SenesTech narrowed its net loss to $1.3 million in Q3 2025, a 14.2% reduction from the $1.51 million loss in Q3 2024. The EPS loss improved to $0.28 from $2.07 per share, reflecting a 86.5% reduction. While the adjusted EBITDA loss of $1.2 million marked a record improvement, the company remains unprofitable, with ongoing losses over the past decade in the corresponding quarter.

Price Action

Following the earnings release, SenesTech’s stock experienced a 4.41% increase in the latest trading day, building on a 3.40% gain over the past week. However, the stock faced a 16.80% decline month-to-date, indicating mixed investor sentiment. The price action reflects both short-term optimism and longer-term volatility.

CEO Commentary

Joel Fruendt, CEO, emphasized the 77% year-over-year growth in Evolve® Rodent Birth Control sales, which now dominate 85% of revenue. He highlighted a multi-channel distribution strategy—e-commerce, municipal programs, and pest management partnerships—that drove 62.8% gross margins and a record $10.2 million cash balance. Fruendt expressed confidence in achieving breakeven goals, citing the company’s strong liquidity and expanding market adoption.

Guidance

The company plans to leverage momentum in municipal deployments and e-commerce expansion, particularly through Amazon, Walmart.com, and Ace Hardware. While no specific revenue targets were provided, SenesTech emphasized long-term growth in pest management professional channels and operational efficiency. The CEO reiterated that the $10.2 million cash balance supports the path to profitability without further equity raises.

Additional News

1. E-commerce Expansion: Evolve® Rodent Birth Control is now available on Lowes.com and HomeDepot.com, with e-commerce sales up 55% year-over-year.

2. Retail Partnerships: Ace Hardware expanded coverage, and Bradley Caldwell, a wholesaler, began ordering Evolve products for 8,000+ retail locations.

3. International Expansion: The Belize Raptor Center became an official distributor in Belize, marking SenesTech’s first international market for Evolve®.

Post-Earnings Price Action Review

The stock’s post-earnings trajectory reflects a complex mix of short-term optimism and long-term skepticism. A 4.41% daily gain and 3.40% weekly rise suggest investor confidence in the company’s strategic progress, particularly in e-commerce and municipal adoption. However, the 16.80% month-to-date decline highlights lingering concerns about profitability and debt sustainability. Analysts note that while the $10.2 million cash balance provides runway, the path to breakeven remains uncertain without significant cost reductions or revenue acceleration.

Financial Health Analysis

SenesTech’s balance sheet shows strong liquidity, with a current ratio of 9.23 and $10.2 million in cash. However, a negative operating margin of -290.54% and an EPS of -$5.44 underscore persistent profitability challenges. The company’s focus on high-margin Evolve products and cost discipline may eventually offset these headwinds, but near-term risks include legal costs and international regulatory hurdles.

Conclusion

SenesTech’s Q3 2025 results highlight progress in revenue growth and cost management, with Evolve® driving the majority of sales. While the adjusted EBITDA loss improvement is a positive sign, the company’s path to profitability remains uncertain. Investors will need to monitor cash burn, expansion into new markets, and operational efficiency to gauge long-term viability.